2-ethyl-5-fluorophenol | 1147351-77-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-ethyl-5-fluorophenol
• CAS: 1147351-77-6
• 化学式: C₈H₉FO
• 分子量: 140.157
• InChiKey: OELSRILEABAUDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-ethyl-5-fluorophenol 在 N-溴代丁二酰亚胺(NBS) 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成 1-(benzyloxy)-4-bromo-2-ethyl-5-fluorobenzene
  参考文献：
  名称：

  UROLITHIN DERIVATIVES AND THERAPEUTIC USES

  摘要：

  Disclosed are compounds, compositions, and methods useful for inhibiting ferroptosis in a subject in need thereof.

  公开号：

  US20240051933A1
• 作为产物：
  描述：

  5-fluoro-2-(1-hydroxyethyl)phenol 在 三乙基硅烷 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以55 %的产率得到2-ethyl-5-fluorophenol
  参考文献：
  名称：

  UROLITHIN DERIVATIVES AND THERAPEUTIC USES

  摘要：

  Disclosed are compounds, compositions, and methods useful for inhibiting ferroptosis in a subject in need thereof.

  公开号：

  US20240051933A1

文献信息

• Heterocyclic compounds as inhibitors of factor VIIa
  申请人：Glunz W. Peter

  公开号：US20060211720A1

  公开（公告）日：2006-09-21

  The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel heterocyclic compounds, or a stereoisomer or pharmaceutically acceptable salt, solvate, or prodrug form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

  本发明一般涉及抑制丝氨酸蛋白酶的化合物。具体而言，它涉及新颖的杂环化合物，或其立体异构体或药用可接受的盐、溶剂合物或前药形式，这些化合物可用作凝血级联中丝氨酸蛋白酶的选择性抑制剂；例如凝血酶、第VIIa因子、第Xa因子、第XIa因子、第IXa因子和/或血浆激肽。具体而言，它涉及第VIIa因子抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用它们的方法。
• HETEROCYCLIC CETP INHIBITORS
  申请人：Salvati E. Mark

  公开号：US20070161685A1

  公开（公告）日：2007-07-12

  Compounds of formula Ia and Ib wherein A, B, C and R 1 are described herein.

  式Ia和Ib的化合物 其中A、B、C和R1 如本文所述。
• Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
  申请人：Borchardt Allen

  公开号：US20050176701A1

  公开（公告）日：2005-08-11

  The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R 1 and R 2 , are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  这项发明涉及公式1的化合物，以及其药学上可接受的盐、溶剂化合物、前药和代谢物，其中W、Z、R1和R2如本文所定义。该发明还涉及通过给哺乳动物施用公式1的化合物来治疗丙型肝炎病毒的方法，以及用于治疗这类疾病的含有公式1化合物的药物组合物。该发明还涉及制备公式1化合物的方法。
• [EN] (E)-N-{3- [1-(8-FLUORO-11H-10-OXA-1-AZA-DIBENZO [A,D] CYCL0HEPTEN-5YLIDENE)-PROPYL]-PHENYL }-METHYNSULFON AMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID<br/>[FR] (E)-N-{3-[1-(8-FLUORO-11H-10-OXA-1-AZA-DIBENZO[A,D]CYCLOHEPTÈN-5-YLIDÈNE)-PROPYL]-PHÉNYL}-MÉTHYLSULFONAMIDE EN TANT QUE MODULATEUR DU RÉCEPTEUR DE GLUCOCORTICOÏDE POUR LE TRAITEMENT D'UNE ARTHRITE RHUMATOÏDE
  申请人：LILLY CO ELI

  公开号：WO2009089312A1

  公开（公告）日：2009-07-16

  The present invention provides Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and discloses methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof.

  本发明提供化合物(I)或其药学上可接受的盐；包含化合物(I)与一种或多种药学上可接受的载体、辅料或稀释剂的制药组合物；并揭示了治疗炎症和免疫性疾病的方法，包括向需要治疗的患者施用有效量的化合物(I)或其药学上可接受的盐。
• INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME
  申请人：Borchardt Allen

  公开号：US20060189681A1

  公开（公告）日：2006-08-24

  The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R 1 and R 2 , are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  本发明涉及式1的化合物以及其药学上可接受的盐、溶剂合物、前药和代谢物，其中W、Z、R1和R2如本文所定义。本发明还涉及通过给哺乳动物投予式1的化合物来治疗丙型肝炎病毒的方法，以及包含式1的化合物的用于治疗此类疾病的制药组合物。本发明还涉及制备式1的化合物的方法。